97057 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
Sub-classes:RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT
#2AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF
#3CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER
#4SWITCH RECEPTORS AND MODIFIED IMMUNE CELLS
#5GENETIC ENGINEERING OF ENDOGENOUS PROTEINS
#6ANTI-IL 18BP ANTIBODIES
#7INDUCIBLE CHIMERIC CYTOKINE RECEPTORS
#8COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR
#9METHODS FOR PRODUCING RED BLOOD CELLS
#10COMPOSITION OF MRNA-ENCODED IL15 FUSION PROTEINS AND METHODS OF USE THEREOF
#11BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF
#12SOLUBLE THROMBOPOIETIN RECEPTOR FRAGMENTS AND USES THEREOF
#13IL-6 INHIBITOR AS TREATMENT FOR NEPHROPATHY
#14IL-15-BASED FUSIONS TO IL-12 AND IL-18
#15METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
#16AGONISTIC ANTIBODIES THAT BIND CD40
#17CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#18C-KIT ANTIBODIES
#19CONSTITUTIVELY ACTIVE CHIMERIC CYTOKINE RECEPTORS
#20IL-15-based fusions to IL-12 and IL-18
#21GENETICALLY MODIFIED BACTERIA AND METHODS FOR GENETIC MODIFICATION OF BACTERIA
#22CONSTITUTIVELY ACTIVE CYTOKINE RECEPTORS FOR CELL THERAPY
#23ANTI-IL 18BP ANTIBODIES
#24NON-MEIOTIC ALLELE INTROGRESSION
#25CELLULAR THERAPY TO SUPPRESS IMMUNE RESPONSE
#26MODIFICATION OF EPOR-ENCODING NUCLEIC ACIDS
#27THERAPEUTIC MOLECULES
#28IL-15-BASED FUSIONS TO IL-12 AND IL-18
#29BTLA Fusion Protein Agonists and Uses Thereof
#30METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES
#31FC-DERIVED POLYPEPTIDES
#32METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR
#33METHODS FOR TREATING HIGH RISK MYELODYSPLASTIC SYNDROMES
#34IL-15-based fusions to IL-12 and IL-18
#35EFFICIENT NON-MEIOTIC ALLELE INTROGRESSION IN LIVESTOCK
#36NK CELLS OR T CELLS EXPRESSING CHIMERIC HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE
#37METHODS OF REDIRECTING OF IL-2 TO TARGET CELLS OF INTEREST
#38SYSTEMS AND METHODS FOR ENHANCED IMMUNOTHERAPIES
#39COMPOSITIONS AND METHODS FOR AUTOIMMUNITY REGULATION
#40IL-15-based fusions to IL-12 and IL-18
#41MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF
#42RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
#43Cells expressing recombinant growth factor receptors
#44C-KIT antibodies and method for treating cancer with such
#45FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF
#46ENGINEERED OPTIMIZED CYTOKINE COMPOSITIONS
#47DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS
#48A METHOD OF ENGINEERING NATURAL KILLER CELLS TO TARGET CD70-POSITIVE TUMORS
#49HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES
#50COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES COMPRISING CCR2
#51Nucleic acid constructs encoding chimeric NK receptor, cells containing, and therapeutic use thereof
#52CHIMERIC RECEPTOR SENSORS
#53IL-15-based fusions to IL-12 and IL-18
#54DNA CONSTRUCT FOR TARGETING THERAPEUTIC MOLECULES TO DISEASED TISSUE BY IMMUNE CELLS
#55Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR
#56CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER
#57METHODS OF B CELL EXPANSION FOR USE IN CELL THERAPY
#58GENETICALLY MODIFIED NK CELLS AND USES THEREOF
#59METHOD FOR PRODUCING CELL POPULATION CONTAINING CAR-EXPRESSING IMMUNE CELLS
#60ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
#61IMMUNOMODULATORY PROTEINS WITH TUNABLE AFFINITIES
#62Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same
#63COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR
#64METHODS AND COMPOSITIONS FOR TREATING ULCERS
#65MULTI-TARGET CHIMERIC ANTIGEN RECEPTOR
#66IL-15-based fusions to IL-12 and IL-18
#67BTLA fusion protein agonists and uses thereof
#68THERAPEUTIC INDUCTION OF TOLERANCE USING RECOMBINANT CELL SURFACE ANTIGENS
#69Soluble leukemia inhibitory factor receptor polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
#70Heterotandem bicyclic peptide complexes
#71GENETIC ENGINEERING OF ENDOGENOUS PROTEINS
#72RECEPTOR INHIBITION BY PHOSPHATASE RECRUITMENT
#73NON-MEIOTIC ALLELE INTROGRESSION
#74AGONISTIC ANTIBODIES THAT BIND CD40
#75BINDING-TRIGGERED TRANSCRIPTIONAL SWITCHES AND METHODS OF USE THEREOF
#76Engineered Optimized Cytokine Compositions
#77CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#78IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
#79CD5 CHIMERIC ANTIGEN RECEPTOR FOR ADOPTIVE T CELL THERAPY
#80Agonistic antibodies that bind human CD40 and uses thereof
#81Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
#82Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies
#83HUMANIZED TRANSGENIC ANIMAL
#84METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALS
#85Methods and compositions for targeted cleavage and recombination
#86Constitutively active chimeric cytokine receptors
#87Method for treating cancer with c-kit antibodies
#88Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
#89Chimeric NK receptor and methods for treating cancer
#90Genetically modified bacteria and methods for genetic modification of bacteria
#91Recombinant NK cells expressing co-stimulatory molecules
#92Methods and compositions for treating ulcers
#93MULTI-FUNCTION AND MULTI-TARGETING CAR SYSTEM AND METHODS FOR USE THEREOF
#94Non-meiotic allele introgression
#95Non-meiotic allele introgression
#96TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLS
#97C-KIT antibodies
#98Chimeric antigen receptors and uses thereof
#99Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same
#100Chimeric NK receptor and methods for treating cancer
#101Non-meiotic allele introgression
#102Cytokine receptor genes and the use thereof to enhance therapy
#103Agonistic antibodies that bind CD40
#104Heterotandem bicyclic peptide complexes
#105Inducible chimeric cytokine receptors
#106COMPOSITIONS AND METHODS FOR TREATING CARDIOMYOPATHY
#107Compositions comprising antisense-encoded erythropoietin receptor and use thereof
#108GENETICALLY MODIFIED ANIMALS HAVING INCREASED HEAT TOLERANCE
#109EFFICIENT NON-MEIOTIC ALLELE INTROGRESSION IN LIVESTOCK
#110Constitutively active cytokine receptors for cell therapy
#111TSLP inhibitors
#112Efficient non-meiotic allele introgression in livestock
#113Cancer examination method and examination kit
#114Engineered antigen presenting cells and uses thereof
#115Skin probiotic formulation
#116IL-15-based fusions to IL-12 and IL-18
#117Binding-triggered transcriptional switches and methods of use thereof
#118ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR MONOCLONAL ANTIBODIES
#119Method of manufacturing a protein by perfusion in media with a low amino acid concentration
#120Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
#121Methods of treating a subject having heart failure that include detecting levels of galectin-3 and soluble ST2
#122Antibody for immunoassay and method for preparing same
#123Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
#124Immunomodulatory proteins with tunable affinities
#125STABLE PHARMACEUTICAL COMPOSITION OF TNFR:FC FUSION PROTEIN
#126Binding-triggered transcriptional switches and methods of use thereof
#127Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide
#128CD5 chimeric antigen receptor for adoptive T cell therapy
#129Antibodies that bind to CCR6 and their uses
#130Binding-triggered transcriptional switches and methods of use thereof
#131Nucleic acids encoding agonistic antibodies that bind CD40
#132Cytokine receptor genes and the use thereof to enhance therapy
#133Efficient non-meiotic allele introgression
#134NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR10
#135ANTI-TUMOR ANTIBODY-TUMOR SUPPRESSOR FUSION PROTEIN COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF CANCER
#136Substrates for FLT3 kinase and uses thereof
#137Methods of treating liver conditions using Notch2 antagonists
#138Methods and compositions for targeted cleavage and recombination
#139Methods of producing a zcytor17 heterodimeric cytokine receptor
#140Human Notch1 decoys
#141Methods and compositions for transducing lymphocytes and regulated expansion thereof
#142Methods of lowering serum cholesterol
#143Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof
#144BIPARTITE AND TRIPARTITE SIGNALING IMMUNE CELLS
#145Human IL1-R1 derived inhibitor of IL-1β
#146Variants of DR3 and use thereof
#147GENETICALLY MODIFIED ANIMALS HAVING INCREASED HEAT TOLERANCE
#148Methods of treating or selecting a treatment for a subject having heart failure that include detecting levels of galectin-3 and soluble ST2
#149Human leucine zipper/trail recombinant polypeptides
#150Anti-human TSLP receptor antibody
#151Materials and methods for producing animals with short hair
#152ZCYTOR17 heterodimeric cytokine receptor
#153Anti-human TSLP receptor antibody
#154Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
#155Use of GPR83 to identify pruritus-related substances
#156Methods for treating or ameliorating multiple sclerosis
#157Method for screening mutant microorganism overproducing target metabolite using synthetic suicide genetic circuit
#158Genetically modified bacteria and methods for genetic modification of bacteria
#159Antibodies that bind to cytokine receptor NR10
#160Template-fixed peptidomimetics with CXCR7 modulating activity
#161Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent
#162Chimeric NK receptor and methods for treating cancer
#163Method of manufacturing a protein by perfusion in media with a low amino acid concentration
#164LIVESTOCK WITH GENETICALLY MODIFIED PROLACTIN RECEPTOR
#165Efficient non-meiotic allele introgression
#166Methods of treating liver conditions using Notch2 antagonists
#167Chimeric molecule involving oligomerized FasL extracellular domain
#168METHODS OF MODULATING IMMUNOLOGICAL RESPONSES BY ADMINISTERING TRUNCATED BAFF RECEPTORS
#169Methods and compositions for targeted cleavage and recombination
#170Multivalent fibronectin based scaffold domain proteins
#171Chimeric human-llama antigens and methods of use
#172Human Notch1 decoys
#173Compositions for treating glioma
#174Methods of determining efficacy of treatment in a subject having heart failure
#175ZCYTOR17 heterodimeric cytokine receptor
#176Polypeptide compounds for inhibiting angiogenesis and tumor growth
#177Modulators of Plexin B2 activity
#178Methods and compositions for targeted cleavage and recombination
#179Humanized transgenic animal
#180Template-fixed peptidomimetics with CXCR7 modulating activity
#181Method of treating B cell cancers by administering truncated BAFF receptors
#182ZCYTOR17 heterodimeric cytokine receptor polynucleotides
#183METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS
#184Methods of using antibodies to block human thymic stromal lymphopoietin (TSLP) receptor activity
#185Methods for identifying a GLP-1 secretagogue
#186Agonist antibody to human thrombopoietin receptor
#187Polynucleotides encoding antibodies to cytokine receptor zcytor17
#188METHODS OF TREATING IL-TIF ASSOCIATED INFLAMMATORY OR IMMUNE DISEASES USING ANTIBODIES AGAINST SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS
#189Multivalent fibronectin based scaffold domain proteins
#190CRLF2 IN PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#191POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
#192Methods predicting risk of an adverse clinical outcome
#193Antigenic determinants of human death receptor DR5
#194ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES
#195Cytokine zalpha11 ligand
#196Methods for producing cytokine receptor ZALPHA11
#197MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS
#198Mammalian receptor proteins DCRS5; methods of treatment
#199Methods and compositions for inhibiting viral entry into cells
#200HUMAN CYTOKINE RECEPTOR
#201ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE
#202Agonist antibody to human thrombopoietin receptor
#203B LYMPHOCYTE STIMULATOR ASSAYS
#204Methods of treatment using antibodies to Neutrokine-alpha
#205Chimeric NK receptor and methods for treating cancer
#206CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#207Method of treating immunological disorders by administering truncated BAFF receptors
#208PROSAPOSIN AS A NEUROTROPHIC FACTOR
#209Antibodies to thymic stromal lymphopoietin (TSLP) receptor molecules and uses thereof
#210Antibodies to cytokine receptor ZCYTOR17
#211METHODS AND MATERIALS RELATING TO CD84-LIKE POLYPEPTIDES AND POLYNUCLEOTIDES
#212Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders
#213Nucleic acids encoding DCRS5
#214Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
#215PROSAPOSIN AS A NEUROTROPHIC FACTOR
#216Methods for detecting modulators of cytokine receptor zalpha11
#217GRANULOCYTE COLONY STIMULATING FACTOR
#218TGF-Beta Antagonist Multi-Target Binding Proteins
#219LSR RECEPTOR, ITS ACTIVITY, ITS CLONING, AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS
#220NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#221TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS
#222B LYMPHOCYTE STIMULATOR ASSAYS
#223POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
#224Mammalian receptor protein DCRS5; methods of treatment
#225EphA4 Polypeptide Having a Novel Activity and Use Thereof
#226Modulation of T cell Differentiation for the treatment of T helper cell mediated diseases
#227LEPTIN FUSION PROTEINS
#228ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE
#229Methods of treating IL-TIF associated inflammatory or immune diseases using antibodies against soluble zcytor 11 cytokine receptors
#230POLYNUCLEOTIDES ENCODING CLASS II CYTOKINE RECEPTOR-7
#231NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#232Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling
#233Methods and compositions for targeted cleavage and recombination
#234MUTATIONAL ANALYSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS
#235Combination Therapy to Treat Persistent Viral Infections
#236METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA
#237Human cytokine receptor
#238MAMMALIAN ZCYTOR 11
#239Cytokine zalpha11 ligand antibodies
#240CYTOKINE ZALPHA11 LIGAND ANTIBODIES
#241Method of suppressing or reducing IL-TIF-induced inflammation, or treating associated conditions thereof, using Zcytor16
#242Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
#243MEMORY AND LEARNING IMPAIRMENTS ASSOCIATED WITH DISRUPTION OF EPHRIN RECEPTOR A6 (EphA6) GENE
#244Novel secreted immunomodulatory proteins and uses thereof
#245Mammalian receptor proteins DCRS5; method of treatment
#246CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#247CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#248Polypeptide compounds for inhibiting angiogenesis and tumor growth
#249DCRS5 polypeptides
#250NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF
#251Hemopoietin receptor protein, NR10
#252Hemopoietin receptor protein, NR10
#253Method of using interferon-like potein ZCYTO20 (IL-28A) or ZCYTO22(IL-28B) to treat hepatitis B
#254Cytokine zalpha11 ligand antibodies
#255Antibodies to cytokine receptor zalpha11
#256Diagnostic Assay
#257NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
#258Truncated BAFF receptors
#259Receptor-based interaction trap
#260Fusion protein capable of binding VEGF-A and TNF-alpha
#261TOLL-LIKE RECEPTOR BINDING EPITOPE AND COMPOSITIONS FOR BINDING THERETO
#262MU-1, member of the cytokine receptor family
#263Soluble IL-17RCx4 and fusion proteins thereof
#264Human cytokine receptor
#265POLYNUCLEOTIDES ENCODING CLASS II CYTOKINE RECEPTOR-7
#266NUCLEIC ACID COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
#267DNA coding for polypeptide fusion
#268MAMMALIAN ZCYTOR 11
#269CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#270Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
#271Active antiangiogenic therapy
#272Soluble Zcytor 11 Cytokine Receptors
#273METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS
#274Chimeric NK receptor and methods for treating cancer
#275DRUG FOR INHIBITING,PREVENTING OR TREATMENT OF RHEUMATOID ARTHRITIS
#276Hemopoietic receptor protein, NR10
#277RECEPTOR THAT BINDS TRAIL
#278Agonist antibody to human thrombopoietin receptor
#279CSF3R polypeptides and uses thereof
#280IL-6 binding proteins
#281Multivalent fibronectin based scaffold domain proteins
#282Methods for identifying a GLP-1 secretagogue
#283Monoclonal antibodies to human CTLA-8 (IL-17A)
#284Processing of EphA4 polypeptide by γ-secretase activity
#285IL-31 RECEPTOR ANTIBODIES
#286CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
#287Human cytokine receptor
#288Lipolysis stimulated receptor (LSR) specific antibodies
#289Method of identifying a binding partner to a cytokine receptor common gamma chain like polypeptide
#290Embryonic stem cells capable of differentiating into desired cell lines
#291Inhibitor of vascular endothelial cell growth factor
#292Polypeptide fusion
#293PURIFIED MAMMALIAN CTLA-8 ANTIGENS AND RELATED REAGENTS
#294Chimeric NK receptor and methods for treating cancer
#295Neutrokine-alpha antibodies and methods of use thereof
#296Polypeptide compounds for inhibiting angiogenesis and tumor growth
#297Antibodies to ZCYTO20 (IL-28A) and ZCYTO22 (IL-28B)
#298Methods of inhibiting proliferation or immunoglobulin production of B cells using human tumor necrosis factor receptor TR-17 polypeptides
#299ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
#300NOVEL HEMOPOIETIN RECEPTOR PROTEIN, NR12